Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

por Repetto-Llamazares, Ada H V, Larsen, Roy H, Mollatt, Camilla, Lassmann, Michael, Dahle, Jostein
Publicado 2013

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice

por Repetto-Llamazares, Ada H. V., Larsen, Roy H., Giusti, Anna Maria, Riccardi, Elena, Bruland, Øyvind S., Selbo, Pål Kristian, Dahle, Jostein
Publicado 2014

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

por Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H.V.
Publicado 2020

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

por Repetto-Llamazares, Ada H. V., Larsen, Roy H., Patzke, Sebastian, Fleten, Karianne G., Didierlaurent, David, Pichard, Alexandre, Pouget, Jean Pierre, Dahle, Jostein
Publicado 2015